Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation

Type 1 vasoactive intestinal peptide receptor (VIP1R) is expressed in many secretory epithelial cells. We investigated VIP1R expression as a marker of prostate secretory epithelial differentiation in normal and malignant prostate tissues and in PC‐3 human prostate cancer cells either lacking or expressing a functional androgen receptor.

[1]  H. Klocker,et al.  Expression, structure, and function of androgen receptor in advanced prostatic carcinoma , 1998, The Prostate.

[2]  X. Zhu,et al.  Steroid-independent activation of androgen receptor in androgen-independent prostate cancer A possible role for the MAP kinase signal transduction pathway? , 1997, Molecular and Cellular Endocrinology.

[3]  M. Webber,et al.  Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines , 1997, The Prostate.

[4]  L. Chung,et al.  Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Webber,et al.  Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part I. Cell markers and immortalized nontumorigenic cell lines , 1996, The Prostate.

[6]  P. J. Gkonos,et al.  Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells , 1996, Regulatory Peptides.

[7]  K. Burnstein,et al.  Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells , 1996, Steroids.

[8]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[9]  T. Moody,et al.  Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. , 1996, Cancer Research.

[10]  J C Reubi,et al.  In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  B. Roos,et al.  Neuroendocrine peptides stimulate adenyl cyclase in normal and malignant prostate cells , 1995, Regulatory Peptides.

[12]  E. Goetzl,et al.  Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[14]  E. Goetzl,et al.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.

[15]  T. Moody,et al.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Logothetis,et al.  Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. , 1993, The Journal of urology.

[17]  S. Said,et al.  Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody. , 1993, Life sciences.

[18]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[19]  R. Ostenson,et al.  Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[21]  B. Roos,et al.  Thyrotropin-releasing hormone gene expression in normal thyroid parafollicular cells. , 1989, Molecular endocrinology.

[22]  G. Dehmer,et al.  Vasoactive Intestinal Peptide as a Coronary Vasodilator , 1988, Annals of the New York Academy of Sciences.

[23]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[24]  W. Vermaak,et al.  Fatty acid induced changes in circulating total and free thyroid hormones: in vivo effects and methodological artefacts , 1986, Journal of endocrinological investigation.

[25]  M. Carmena,et al.  Cyclic AMP response to vasoactive intestinal peptide andβ-adrenergic or cholinergic agonists in isolated epithelial cells of rat ventral prostate , 1985, Bioscience reports.

[26]  P. Barnes,et al.  Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.